Cargando…

Umbilical cord blood: A promising source for allogeneic CAR-T cells

Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dian-Dian, Hong, Wei-Cong, Qiu, Kun-Yin, Li, Xin-Yu, Liu, Yong, Zhu, Li-Wen, Lai, Wei-Xin, Chen, Han-, Yang, Hua-Qing, Xu, Lu-Hong, Fang, Jian-Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373021/
https://www.ncbi.nlm.nih.gov/pubmed/35965561
http://dx.doi.org/10.3389/fonc.2022.944248
_version_ 1784767512385159168
author Liu, Dian-Dian
Hong, Wei-Cong
Qiu, Kun-Yin
Li, Xin-Yu
Liu, Yong
Zhu, Li-Wen
Lai, Wei-Xin
Chen, Han-
Yang, Hua-Qing
Xu, Lu-Hong
Fang, Jian-Pei
author_facet Liu, Dian-Dian
Hong, Wei-Cong
Qiu, Kun-Yin
Li, Xin-Yu
Liu, Yong
Zhu, Li-Wen
Lai, Wei-Xin
Chen, Han-
Yang, Hua-Qing
Xu, Lu-Hong
Fang, Jian-Pei
author_sort Liu, Dian-Dian
collection PubMed
description Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations, allogeneic CAR-T cells may be used as effective substitutes; however, which source would be the best substitute is unclear. In this study, we compared the immunophenotype and antitumor efficacy of anti-CD19 CAR-T cells derived from healthy donor cord blood (CB), healthy donor peripheral blood (PB), and PB of B-ALL patients [PB (patient)] in vitro and NOD-Prkdcem26cd52Il2rgem26Cd22/Nju (NCG)-immunodeficient mice, respectively. The results revealed that CAR-T cells derived from healthy donor CB and PB showed a higher proportion of naive T cells and longer tumor suppression in tumor-bearing mice than those of PB (patient). PB (patient) CAR-T cells had a higher proportion of regulatory T cells (Treg cells) and released high levels of interluekin-10 (IL-10), which also suggest a poor prognosis. Thus, CAR-T cells derived from healthy donors have better antitumor efficacy than CAR-T cells derived from PB (patient), and CB may be a good source of allogeneic CAR-T cells.
format Online
Article
Text
id pubmed-9373021
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93730212022-08-13 Umbilical cord blood: A promising source for allogeneic CAR-T cells Liu, Dian-Dian Hong, Wei-Cong Qiu, Kun-Yin Li, Xin-Yu Liu, Yong Zhu, Li-Wen Lai, Wei-Xin Chen, Han- Yang, Hua-Qing Xu, Lu-Hong Fang, Jian-Pei Front Oncol Oncology Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations, allogeneic CAR-T cells may be used as effective substitutes; however, which source would be the best substitute is unclear. In this study, we compared the immunophenotype and antitumor efficacy of anti-CD19 CAR-T cells derived from healthy donor cord blood (CB), healthy donor peripheral blood (PB), and PB of B-ALL patients [PB (patient)] in vitro and NOD-Prkdcem26cd52Il2rgem26Cd22/Nju (NCG)-immunodeficient mice, respectively. The results revealed that CAR-T cells derived from healthy donor CB and PB showed a higher proportion of naive T cells and longer tumor suppression in tumor-bearing mice than those of PB (patient). PB (patient) CAR-T cells had a higher proportion of regulatory T cells (Treg cells) and released high levels of interluekin-10 (IL-10), which also suggest a poor prognosis. Thus, CAR-T cells derived from healthy donors have better antitumor efficacy than CAR-T cells derived from PB (patient), and CB may be a good source of allogeneic CAR-T cells. Frontiers Media S.A. 2022-07-29 /pmc/articles/PMC9373021/ /pubmed/35965561 http://dx.doi.org/10.3389/fonc.2022.944248 Text en Copyright © 2022 Liu, Hong, Qiu, Li, Liu, Zhu, Lai, Chen, Yang, Xu and Fang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Dian-Dian
Hong, Wei-Cong
Qiu, Kun-Yin
Li, Xin-Yu
Liu, Yong
Zhu, Li-Wen
Lai, Wei-Xin
Chen, Han-
Yang, Hua-Qing
Xu, Lu-Hong
Fang, Jian-Pei
Umbilical cord blood: A promising source for allogeneic CAR-T cells
title Umbilical cord blood: A promising source for allogeneic CAR-T cells
title_full Umbilical cord blood: A promising source for allogeneic CAR-T cells
title_fullStr Umbilical cord blood: A promising source for allogeneic CAR-T cells
title_full_unstemmed Umbilical cord blood: A promising source for allogeneic CAR-T cells
title_short Umbilical cord blood: A promising source for allogeneic CAR-T cells
title_sort umbilical cord blood: a promising source for allogeneic car-t cells
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373021/
https://www.ncbi.nlm.nih.gov/pubmed/35965561
http://dx.doi.org/10.3389/fonc.2022.944248
work_keys_str_mv AT liudiandian umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT hongweicong umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT qiukunyin umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT lixinyu umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT liuyong umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT zhuliwen umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT laiweixin umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT chenhan umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT yanghuaqing umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT xuluhong umbilicalcordbloodapromisingsourceforallogeneiccartcells
AT fangjianpei umbilicalcordbloodapromisingsourceforallogeneiccartcells